BRIEF-FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation

Ironwood Pharmaceuticals, Inc. Class A

Ironwood Pharmaceuticals, Inc. Class A

IRWD

0.00

May 27 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:

  • FDA APPROVES USE OF LINZESS® (LINACLOTIDE) IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER WITH FUNCTIONAL CONSTIPATION (FC)

  • IRONWOOD PHARMACEUTICALS - LINZESS CONTRAINDICATED IN PATIENTS UNDER 2 YEARS DUE TO RISK OF SERIOUS DEHYDRATION

  • IRONWOOD PHARMACEUTICALS INC: LINZESS IS CONTRAINDICATED IN PATIENTS WITH KNOWN OR SUSPECTED MECHANICAL GASTROINTESTINAL OBSTRUCTION

Source text: ID:nBw81Zz0ra

Further company coverage: IRWD.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.